An interventional study of AESOP service system in Hypertension, sponsored by Taipei Medical University. Completed at 1 site in Taiwan. Per ClinicalTrials.gov, last updated 2018-04-03.
Sponsored by Taipei Medical University · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 117 studies in Hypertension with a site in Taiwan — 18 open to participants now, 21 under way, 5 of them phase 3. Hypertension · Taiwan.
Among the 117 studies in Hypertension with a site in Taiwan, this one is the 84th largest by enrollment of the 90 interventional ones that give a count, is one of 4 that started in 2017, is one of 30 with no phase, and was the 68th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →18 of the 117 studies in Hypertension with a site in Taiwan are open now. Recruiting first, the newest first:
Fu Jen Catholic University · Sites in Taiwan
Ages 18+
Chang Gung University of Science and Technology · Sites in Taiwan
Ages 50+
Kaohsiung Armed Forces General Hospital · Sites in Taiwan
Ages 18–65
New Taipei City Medical Association · Sites in Taiwan
Medtronic Vascular · Sites in Taiwan, Australia, Belgium and 6 more countries
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
117 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 13 · Phase 3 27 · Phase 4 20
First in 2001; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 233 across the 90 interventional studies, 156 across the 25 observational. Of the 76 that completed or were terminated, 24 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 117 have an industry lead sponsor. The 10 most frequent:
Taipei Medical University is the lead sponsor of 257 studies on the registry; 59 are open to participants now.
Taipei Medical University has 3 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
8 of the studies in Hypertension with a site in Taiwan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT07543211National Yang Ming Chiao Tung UniversityEffectiveness of Laser Irradiation on the Veins and Acupoints on Arterial Stiffness in Patients With Cardio-renal Metabolic Syndrome | 2026-12 |
| NCT07222917AstraZenecaA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. | 2026-12-10 |
| NCT07578090Fu Jen Catholic UniversityRegional Innovation in Chronic Disease and Elderly Care | 2026-12-31 |
| NCT07603583Kaohsiung Armed Forces General HospitalAssessment of Heart Rate Variability for Predicting Obstructive Sleep Apnea in Patients With Hypertension | 2026-12-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 117 studies in Hypertension with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Medication errors are common, life-threatening, costly but preventable. Information technology and automated systems are highly efficient for preventing medication errors and therefore widely employed in hospital settings. In this study, investigators would perform a cluster randomized controlled trial of a clinical reminding system that uses DNN and Probabilistic models to detect and notify physicians of inappropriate prescriptions, giving them the opportunity to correct these gaps and increase prescriptions completeness. This study aim is to assess whether or not this system would improve prescription notation for a broad array of patient conditions.
This paper focuses on "Big data" in the knowledge base, using "Data minig" study of DM (Disease-Medication) and MM (Medication-Medication) of relevance to develop associated decision resources system-"the intelligent safety system" (Advanced Electronic Safety of Prescriptions,AESOP Model), and test the system in the clinical environment in hospital can assist physicians when open orders reduce medication errors, the system is named "AESOP Model".
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
18 were assigned to the experimental group
Other: AESOP service system
19 were assigned to the traditional CPOE system
Investigators develop an electronic reminder in CPOE system which notifies physicians when there appears to be an inappropriate prescription. At the time, a physician saves a typed prescription, our system analyzes the patient's medications, diseases and uses the knowledge base to determine whether a medication is uncommonly prescribed to all diseases in a given prescription. If the system detects the common associations of medications and diseases in a given prescription, it considers an appropriate prescription, and, if not, an actionable reminder is shown onscreen. To the right of each suggested uncommon medication is a reason why the reminder is appearing. Physicians can accept the reminder or ignore the reminder.
The acceptance rate of reminder between two groups intervention and control
The primary outcome of this study is the acceptance rate of the reminder, defined as the number of reminders accepted divided by number of unique reminders presented. In certain instances, physicians might see the same reminder serially, so we aggregate presentations and acceptance of the same reminder for the same patients' prescriptions in our calculation of the acceptance rate.
Time frame: 3 months
The changes in the number of reminder for each group
As a secondary outcome, we measure the number of inappropriate prescriptions rate documented in the two groups during the two time periods and calculate the unadjusted relative rate of inappropriateness notation in the intervention group by comparing the number of inappropriateness recorded in the intervention arm during the intervention period to all other groups. The unadjusted relative rate is defined as the ratio (errorsintervention-post/errorscontrol-post)/ (errorsintervention-pre/errorscontrol-pre).
Time frame: 3 months
Ran from May 2017 to primary completion in Dec 2017, 7 months.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 7 months is below that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.